EUVIMED · CrossrefZeitschrift
The Breast
ISSN 0960-9776 · Elsevier BV
Neueste Artikel
8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)
Performance of large language models in ambiguous treatment scenarios of early breast cancer
Knowledge gaps and future perspectives for the definition, diagnostics and treatment of isolated locoregional recurrent breast cancer
Longitudinal trajectories of menopausal symptoms in women receiving endocrine therapy for breast cancer compared with natural menopause
Impact of old age, comorbidity, and polypharmacy on adjuvant endocrine therapy for patients with early-stage breast cancer
Can CanAssist Breast guide the duration of extended endocrine therapy?
Use of prepectoral polyurethane coated implants in the setting of radiotherapy: the OPBC-09 PRExRT retrospective cohort study
Incidence and mortality of breast cancer among adolescent and young adult women worldwide in 2022 and projections for 2040: Implications for surgery
Impact of multidisciplinary tumor meetings on clinical outcomes, treatment concordance, and guideline adherence in breast cancer: a systematic review with emphasis on older patients
Can surgical axillary staging be safely omitted in early-stage invasive lobular carcinoma? Results from a large multicenter retrospective study
Reirradiation After Repeat Breast Conserving Treatment: Contemporary Evidence, Technical Approaches, and Expert Recommendations
End-of-life care values and treatment preferences among Japanese breast cancer patients and families: A dyadic cross-sectional study
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial
Identifying pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancer
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial
From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2– breast cancer
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials
Beyond the first dose: Systematic review on external beam radiotherapy for locoregional breast cancer recurrence
Impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery on intracranial control and radionecrosis risk in HER2-positive or -low breast cancer brain metastases
Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody–drug conjugates in breast cancer
Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional survey
Secondary dry eye disease in breast cancer patients: a pilot study
Comparative validation of PREDICT versions 3.1 and 2.2 for overall survival in the Dutch breast cancer population
Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort
Jahrgänge
2026 · 1922025 · 7512024 · 1832023 · 6622022 · 1752021 · 5152020 · 2162019 · 7302018 · 2912017 · 7522016 · 1872015 · 7352014 · 2542013 · 3872012 · 2532011 · 5742010 · 1252009 · 3702008 · 1422007 · 3522006 · 1662005 · 2822004 · 1182003 · 2622002 · 1262001 · 1612000 · 811999 · 891998 · 1001997 · 3311996 · 1341995 · 2141994 · 801993 · 1791992 · 154
EUVIMED